Gremlin 2 is Repressed in Invasive Endometrial Cancer and Inhibits Cell Growth In Vitro

Hiroshi Tsubamoto; Kazuko Sakata; Riya Sakane; Kayo Inoue; Hiroaki Shibahara; Hiroyuki Hao; Seiichi Hirota

Gremlin 2 is Repressed in Invasive Endometrial Cancer and Inhibits Cell Growth In Vitro

Anticancer Res. 2016 Jan;36(1):199-203.

Authors

Hiroshi Tsubamoto¹, Kazuko Sakata², Riya Sakane², Kayo Inoue², Hiroaki Shibahara², Hiroyuki Hao³, Seiichi Hirota³

Affiliations

¹ Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan tsuba@hyo-med.ac.jp.
² Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
³ Department of Surgical Pathology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.

PMID: 26722044

Abstract

Background: There exist limited therapeutic opportunities regarding the treatment of endometrial cancer (EC), and novel therapies based on the molecular profiling of EC cells are required.

Materials and methods: We used microarray analysis of EC tumour samples in order to identify tumour-specific changes regarding gene expression.

Results: It was found that gremlin 2, an inhibitor of bone morphogenetic protein (BMP) signaling, was repressed in EC samples, and that gremlin 2 inhibited tumour cell growth.

Conclusion: Down-regulation of gremlin 2 may lead to carcinogenesis and progression of EC. We suggest that re-activation of gremlin 2-associated pathways could suppress EC progression and should thus be explored as a potential novel therapeutic approach.

Keywords: Gremlin 2; bone morphogenetic proteins; endometrial cancer.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cell Movement
Cell Proliferation
Endometrial Neoplasms / immunology*
Endometrial Neoplasms / pathology
Female
Humans
In Vitro Techniques
Intercellular Signaling Peptides and Proteins / metabolism*
Signal Transduction

Substances

GREM1 protein, human
Intercellular Signaling Peptides and Proteins